Core Insights - The newly launched Huabao Advantage Industry Mixed Fund achieved a first fundraising scale of 5.777 billion yuan, marking a significant success in the recent fund issuance market [1] - The fund's performance reflects strong market confidence in Huabao Fund's active equity investment team, which has been recognized for its impressive investment results [1][2] - Huabao Fund's manager Zheng Yingliang has gained a reputation for outstanding investment performance, with his managed funds achieving over 100% returns in 2025 [2][9] Fund Performance - Zheng Yingliang's managed funds, Huabao Core Advantage Flexible Allocation Mixed Fund and Huabao Large Cap Selected Mixed Fund, reported net value growth rates of 117.17% and 116.03% respectively in 2025, significantly outperforming their benchmarks by over 100 percentage points [2][9] - The Huabao Core Advantage Fund has a three-year net value growth rate of 151.57%, ranking 2nd out of 406 in its category, with an annualized return of 36% [9] Investment Strategy - Zheng Yingliang employs a lifecycle approach to industry investment, focusing on high-growth and mature phases while avoiding industry reshuffling periods [11] - The current investment focus includes three key sectors: artificial intelligence, new energy industry chain, and traditional manufacturing [11] Emerging Fund Managers - A group of emerging fund managers at Huabao Fund, including Ding Jingfei, Tang Hui, Qi Zhen, and Chen Huaiyi, have also demonstrated strong performance, with their funds achieving significant net value growth rates exceeding their benchmarks [13][19] - The investment strategies of these managers reflect a deep understanding of market trends and a commitment to delivering substantial returns to investors [19]

Group 1 - The core point of the article is the successful launch of the Hua Bao Advantage Industry Mixed Fund, which raised 5.777 billion yuan, marking a record high for the fund's sales channels since 2022 [1][22] - The fund management team, led by Zheng Yingliang, has received high recognition from the market, evidenced by the fund's impressive performance and the 5A rating awarded by Tianxiang Investment Consulting [1][22] - The article highlights the strong performance of Hua Bao's funds, particularly those managed by Zheng Yingliang, which have significantly outperformed their benchmarks [3][24] Group 2 - Zheng Yingliang's investment strategy focuses on macro and industry research, emphasizing the importance of understanding the industry lifecycle and avoiding periods of industry reshuffling [27] - The Hua Bao Core Advantage Fund, under Zheng's management, achieved a net value growth rate of 151.57% over the past three years, ranking 2nd out of 406 in its category [26] - The article mentions that Zheng's funds have been heavily invested in high-growth sectors such as artificial intelligence and new energy, contributing to their strong performance [7][26] Group 3 - Other emerging fund managers at Hua Bao, such as Ding Jingfei and Tang Hui, have also demonstrated impressive performance, with their funds achieving significant net value growth rates exceeding their benchmarks [29][32] - The article emphasizes Hua Bao's commitment to building a collaborative investment research team, focusing on various sectors including consumption, cycles, TMT, and new energy [33] - The company aims to enhance its core competitiveness in investment research through a deep integration of investment and research efforts [33]

Core Viewpoint - The recent regulatory changes aim to align the interests of fund managers with those of investors by requiring a significant portion of their performance-based compensation to be invested in the funds they manage, thereby promoting long-term investment strategies and reducing short-term speculative behavior [1][10]. Group 1: Regulatory Changes - Fund managers will need to invest at least 40% of their performance-based compensation into the funds they manage, with a minimum holding period of one year [3][10]. - Senior executives must allocate 30% of their total performance compensation to purchase public funds managed by their company, with at least 60% of that amount (18% of total compensation) directed towards equity funds [2][10]. Group 2: Impact on Fund Management - The new rules are expected to create a stronger bond between fund managers and investors, making them "in the same boat" regarding fund performance [1][10]. - Data shows that in 2023, 136 public fund companies initiated self-purchases, totaling 8,400 instances, indicating a growing trend in self-investment among fund managers [4][6]. Group 3: Performance Metrics - Among actively managed funds with self-purchases exceeding 10 million, nearly 80% achieved positive returns, with an average return of 15.93% [6][8]. - Funds managed by managers who participated in self-purchases demonstrated higher annualized returns over the past three years compared to their peers, indicating that personal investment by managers reflects their management capabilities [8][10]. Group 4: Industry Trends - The number of self-purchases and the amount invested have shown a year-on-year increase, with leading fund companies exhibiting stronger research capabilities and risk management systems [5][6]. - The top ten public fund companies by self-purchase frequency and amount indicate a competitive landscape where established firms are more likely to adapt to long-term performance assessments [5].

Core Viewpoint - The article analyzes the investment capabilities of Qi Zhen, the fund manager of Huabao Health A, highlighting his focus on innovative drugs driven by policy and industry trends, and his ability to generate significant excess returns compared to peers [4][31]. Group 1: Fund Manager Information - Qi Zhen holds a bachelor's degree in biotechnology and a PhD in biology from Shanghai Jiao Tong University, with prior experience in research analysis at Northeast Securities and Anxin Securities [3][6]. - Since February 28, 2023, Qi Zhen has managed Huabao Health A (006881.OF), which has a total scale of 268 million yuan as of September 30, 2025 [7][30]. Group 2: Performance Metrics - Since Qi Zhen's tenure, Huabao Health A has outperformed over 90% of its peers in the pharmaceutical theme fund category, achieving a cumulative excess return of 60.00% after excluding a three-month establishment period [8][11]. - The fund has shown resilience during downturns in the pharmaceutical sector and has quickly rebounded during bullish trends in innovative drugs [11][31]. Group 3: Investment Strategy - Qi Zhen employs a "policy + industry" dual-driven investment framework, focusing on innovative drugs and prioritizing sectors with minimal resistance and strong policy support [4][14]. - The investment strategy emphasizes a balance between growth and certainty, with flexible valuation tolerances based on clinical success rates and management credibility [4][22]. - Qi Zhen prefers long-term holdings with a low turnover rate of 2-3 times annually, making buy/sell decisions based on market conditions and fundamental changes [4][25]. Group 4: Sector Allocation and Stock Selection - The fund's holdings are heavily concentrated in the innovative drug sector, with over 90% of the portfolio allocated to this area, while also flexibly adjusting positions in medical devices and traditional Chinese medicine [16][19]. - Qi Zhen's stock selection process involves detailed analysis of drug mechanisms, clinical data, and market conditions, allowing for dynamic adjustments in valuation [22][23]. Group 5: Future Outlook - With the ongoing development of China's innovative drug industry and the maturation of capital markets, fund managers like Qi Zhen, who possess deep industry insights, are expected to continue generating excess returns [32].